Evidence map›Paper›PMID 38545420›Full record

ArticleSexual medicine2024

A survey of patient tolerance and satisfaction with capsaicin for neuroproliferative vestibulodynia.

Isabella Kopits, Jill M Krapf, Chailee Moss, Theodora Mautz, Jess Holloway, Lilliana Starsiak, Sylvia Lorenzini, Andrew T Goldstein

Open access · goldAbstract read
In one paragraph

Article in Sexual medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Isabella KopitsThe Centers for Vulvovaginal Disorders, Washington, DC 20037, United States.ORCID https://orcid.org/0009-0000-2372-4384
Jill M KrapfThe Centers for Vulvovaginal Disorders, Washington, DC 20037, United States.ORCID https://orcid.org/0000-0002-8695-0570
Chailee MossThe Centers for Vulvovaginal Disorders, Washington, DC 20037, United States.ORCID https://orcid.org/0000-0002-0176-5705
Theodora MautzThe Centers for Vulvovaginal Disorders, Washington, DC 20037, United States.ORCID https://orcid.org/0000-0003-0932-6878
Jess HollowayThe Centers for Vulvovaginal Disorders, Washington, DC 20037, United States.
Lilliana StarsiakThe Centers for Vulvovaginal Disorders, Washington, DC 20037, United States.
Sylvia LorenziniThe Centers for Vulvovaginal Disorders, Washington, DC 20037, United States.
Andrew T GoldsteinThe Centers for Vulvovaginal Disorders, Washington, DC 20037, United States.
George Washington University · USThe Centers · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Topical capsaicin has been used to treat vulvodynia but has been poorly studied for use in neuroproliferative provoked vestibulodynia (PVD); capsaicin decreases allodynia by blocking vanilloid receptors (TRPV1) on C-afferent nociceptors, but the therapy causes discomfort to the point of intolerance in some patients. Aim: The present study evaluated tolerability and efficacy of topical capsaicin to treat neuroproliferative PVD. Methods: Patients with neuroproliferative PVD prescribed 0.025% capsaicin compounded in VersaBase cream were identified through prescription records. Outcome measures included the Female Sexual Function Index (FSFI), the Female Sexual Distress Scale-Revised, and a 22-question questionnaire assessing patient experience and treatment tolerability. Outcomes: Among tolerant patients, capsaicin significantly decreased vestibular pain, but tolerance was highly variable. Results: Twenty-five patients responded to the follow-up questionnaire. The average age at presentation was 30 years (range, 18-52 years). Eighty percent of patients tolerated capsaicin application for the full 20 minutes within a median time of 1 to 2 weeks. Of the 16 patients reporting tolerance to 20-minute application, 12 (60%) experienced improvement in vestibular pain. On an 11-point numeric rating scale, the mean pain score was 8.96 and the median score was 10 with first application. Among all participants, 16 (64%) had reduction in pain during treatment. Fifty-six percent of patients would recommend capsaicin as a treatment for vulvar pain. Qualitative content analysis focused on categories of efficacy, value, and feasibility, which indicated that those able to tolerate the treatment experienced improvement while using the medication. The mean Female Sexual Distress Scale-Revised score was 35.96 at baseline compared with 25.09 at follow-up ( Clinical Implications: Capsaicin is helpful for some patients with PVD, but thorough counseling is important because of highly variable tolerance. Strengths and Limitations: Strengths include examination of a poorly studied therapy and inclusion of narrative responses from patients to inform counseling. Limitations include small sample size, retrospective design, and low survey response rate. Conclusion: Patients should be appropriately selected and thoroughly counseled given high levels of intolerance, but capsaicin therapy may be considered for patients with neuroproliferative PVD who have failed conservative treatments and wish to avoid surgery.

Indexed as

capsaicindyspareuniavestibulodyniavulvar painvulvar vestibulitisvulvodynia

Identifiers

PMID38545420
PMCPMC10971571
OpenAlexW4393239008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.